NRx Pharmaceuticals to Present Depression Treatment Advancements at Noble Capital Markets Conference
NRx Pharmaceuticals will present its innovative depression treatments including a low-dose D-Cycloserine product that enhances Transcranial Magnetic Stimulation effectiveness and discuss expanded clinical operations and VA collaborations for treating suicidal depression and PTSD.
NRx Pharmaceuticals and its wholly owned subsidiary HOPE Therapeutics Inc. announced that Founder, Chairman, and CEO Dr. Jonathan Javitt will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025. The presentation will highlight the company's clinical developments in treating central nervous system disorders, particularly focusing on depression and PTSD treatments that address critical mental health challenges.
Dr. Javitt will discuss the upcoming launch of a low-dose D-Cycloserine product shown to enhance the effectiveness of Transcranial Magnetic Stimulation for depression treatment. This development represents a significant advancement in mental health therapeutics, potentially offering improved outcomes for patients who have not responded adequately to existing treatments. The company's expanded clinical operations in Florida and collaborations with the U.S. Department of Veterans Affairs to treat veterans with suicidal depression and PTSD underscore the broader societal impact of these medical innovations.
NRx Pharmaceuticals is developing multiple therapeutics based on its NMDA platform, including NRX-100, a preservative-free intravenous ketamine that has received Fast Track Designation for treating Suicidal Ideation in Depression, including Bipolar Depression. The company has recently filed an Abbreviated New Drug Application and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner's National Priority Voucher Program for treating suicidal depression. Additional information about the company's pipeline can be found at https://www.nrxpharma.com.
The company's NRX-101, an oral D-cycloserine/lurasidone combination, has been awarded Breakthrough Therapy Designation for treating suicidal bipolar depression. These designations from regulatory authorities highlight the potential significance of these treatments in addressing severe mental health conditions that have limited therapeutic options. The presentation at the Noble Capital Markets conference provides investors and stakeholders with insight into the company's progress and future direction in developing treatments for central nervous system disorders including suicidal depression, chronic pain, and PTSD.
The timing of this presentation coincides with growing recognition of mental health treatment needs, particularly among veteran populations and individuals with treatment-resistant depression. The company's focus on enhancing existing therapies like Transcranial Magnetic Stimulation through pharmacological augmentation represents an important approach in mental health treatment innovation. For additional details about the presentation and company developments, readers can access the full release at https://ibn.fm/KRCWz.